AR108394A1 - Moduladores de la vía de estrés integrada - Google Patents
Moduladores de la vía de estrés integradaInfo
- Publication number
- AR108394A1 AR108394A1 ARP170101182A ARP170101182A AR108394A1 AR 108394 A1 AR108394 A1 AR 108394A1 AR P170101182 A ARP170101182 A AR P170101182A AR P170101182 A ARP170101182 A AR P170101182A AR 108394 A1 AR108394 A1 AR 108394A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered
- halo
- independently
- nrbrc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332284P | 2016-05-05 | 2016-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108394A1 true AR108394A1 (es) | 2018-08-15 |
Family
ID=58710114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101182A AR108394A1 (es) | 2016-05-05 | 2017-05-05 | Moduladores de la vía de estrés integrada |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10864196B2 (enExample) |
| EP (2) | EP3778575A1 (enExample) |
| JP (2) | JP6869331B2 (enExample) |
| CN (1) | CN109641853A (enExample) |
| AR (1) | AR108394A1 (enExample) |
| AU (1) | AU2017260363B2 (enExample) |
| CA (1) | CA3023161A1 (enExample) |
| ES (1) | ES2821790T3 (enExample) |
| PT (1) | PT3452454T (enExample) |
| TW (1) | TW201808914A (enExample) |
| UY (1) | UY37231A (enExample) |
| WO (1) | WO2017193030A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CN108809583B (zh) | 2017-05-05 | 2024-03-26 | 华为技术有限公司 | 传输信号的方法和装置 |
| EP3628043A4 (en) * | 2017-05-15 | 2021-04-28 | Recurium IP Holdings, LLC | ANALGESIC COMPOUNDS |
| CN110730777A (zh) * | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| IL301709B2 (en) | 2017-08-09 | 2025-07-01 | Denali Therapeutics Inc | Compounds, compositions and methods |
| TW201920129A (zh) | 2017-09-01 | 2019-06-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| SG11202004009TA (en) * | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| BR112020008825A2 (pt) * | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | moduladores da via de estresse integrada |
| MX2020004537A (es) * | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Moduladores de la vía integrada del estrés. |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| WO2019183589A1 (en) * | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| US11166942B2 (en) | 2018-06-05 | 2021-11-09 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| US11072610B2 (en) | 2018-09-12 | 2021-07-27 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| WO2020216766A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2021012904A (es) * | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| PH12021552759A1 (en) | 2019-04-30 | 2022-07-04 | Abbvie Inc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| CN114667285B (zh) | 2019-09-26 | 2025-08-08 | 诺华股份有限公司 | 抗病毒吡唑并吡啶酮化合物 |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic acetylcholine m1 receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
| CA3162526A1 (en) | 2020-01-28 | 2021-08-05 | Christopher John Brown | Modulators of the integrated stress response pathway |
| KR20220151635A (ko) | 2020-03-11 | 2022-11-15 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| MX2023004677A (es) | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| ES2997335T3 (en) | 2020-10-22 | 2025-02-17 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| TW202241857A (zh) | 2020-12-18 | 2022-11-01 | 美商戴納立製藥公司 | 化合物之固體形式 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| AU2023384649A1 (en) | 2022-11-21 | 2025-05-22 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212A (en) | 1847-07-31 | Richard m | ||
| US162A (en) | 1837-04-17 | Island | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| CN101475538A (zh) * | 2002-12-20 | 2009-07-08 | 默克公司 | 用作11-β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物 |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| US20070185079A1 (en) | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
| CA2594116A1 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| EP1954287B2 (en) * | 2005-10-31 | 2016-02-24 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
| WO2011087758A1 (en) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| TWI538905B (zh) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| WO2014144952A2 (en) | 2013-03-15 | 2014-09-18 | Peter Walter | Modulators of the eif2alpha pathway |
| WO2015038778A1 (en) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
| US10526294B2 (en) * | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
-
2017
- 2017-05-04 TW TW106114862A patent/TW201808914A/zh unknown
- 2017-05-05 ES ES17724205T patent/ES2821790T3/es active Active
- 2017-05-05 AU AU2017260363A patent/AU2017260363B2/en not_active Expired - Fee Related
- 2017-05-05 CN CN201780042067.3A patent/CN109641853A/zh active Pending
- 2017-05-05 US US16/098,950 patent/US10864196B2/en active Active
- 2017-05-05 AR ARP170101182A patent/AR108394A1/es unknown
- 2017-05-05 EP EP20184319.0A patent/EP3778575A1/en not_active Withdrawn
- 2017-05-05 PT PT177242054T patent/PT3452454T/pt unknown
- 2017-05-05 JP JP2019510574A patent/JP6869331B2/ja not_active Expired - Fee Related
- 2017-05-05 CA CA3023161A patent/CA3023161A1/en not_active Abandoned
- 2017-05-05 EP EP17724205.4A patent/EP3452454B1/en active Active
- 2017-05-05 UY UY0001037231A patent/UY37231A/es not_active Application Discontinuation
- 2017-05-05 WO PCT/US2017/031352 patent/WO2017193030A1/en not_active Ceased
-
2020
- 2020-05-28 US US16/885,766 patent/US20210113532A1/en not_active Abandoned
-
2021
- 2021-04-13 JP JP2021067440A patent/JP2021107415A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY37231A (es) | 2017-11-30 |
| CN109641853A (zh) | 2019-04-16 |
| EP3452454B1 (en) | 2020-07-08 |
| US10864196B2 (en) | 2020-12-15 |
| EP3778575A1 (en) | 2021-02-17 |
| CA3023161A1 (en) | 2017-11-09 |
| AU2017260363B2 (en) | 2021-12-02 |
| AU2017260363A1 (en) | 2018-11-15 |
| US20210113532A1 (en) | 2021-04-22 |
| PT3452454T (pt) | 2020-10-12 |
| JP2021107415A (ja) | 2021-07-29 |
| JP6869331B2 (ja) | 2021-05-12 |
| TW201808914A (zh) | 2018-03-16 |
| WO2017193030A1 (en) | 2017-11-09 |
| ES2821790T8 (es) | 2022-01-03 |
| EP3452454A1 (en) | 2019-03-13 |
| ES2821790T3 (es) | 2021-04-27 |
| JP2019515042A (ja) | 2019-06-06 |
| US20190142806A1 (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108393A1 (es) | Moduladores de la vía de estrés integrada | |
| AR110599A1 (es) | Moduladores de la vía de estrés integrada | |
| AR108395A1 (es) | Moduladores de la vía de estrés integrada | |
| AR118837A1 (es) | Moduladores de la vía integrada del estrés | |
| AR118836A1 (es) | Moduladores de la vía de tensión integrada | |
| AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| AR113820A1 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
| AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| AR101229A1 (es) | Agentes inhibidores de irak4 | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR095339A1 (es) | Compuestos moduladores alostericos de la hemoglobina | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR098965A1 (es) | Derivados de sulfonamidas tricíclicas | |
| AR086113A1 (es) | Isoxazolinas como agentes terapeuticos | |
| AR092173A1 (es) | Inhibidores de la syk | |
| AR097935A1 (es) | Derivados de piridazinonas útiles como herbicidas | |
| AR114188A1 (es) | Moduladores de la vía de estrés integrada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |